An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease (NCT06754280)
An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease: RESET-CKD
🩺 Plain-English Summary (8th-Grade Level)
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
Who can join: Review the eligibility criteria below.
Location: UI Health/University of Illinois Chicago — Chicago, Illinois
Age range: 35 Years to 80 Years
🧪 Interventions in This Study
- RESET-CKD (BEHAVIORAL)
- Attention Control (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- UI Health/University of Illinois Chicago — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 355-4838
Email: mhanna22@uic.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Kidney Disease(CKD)
- Effect of Oral Consumption of a Symbiotic Gelatin on the Presence of Gastrointestinal Symptoms and Quality of Life in People With Chronic Kidney Disease — Toluca,
- Genomic First Testing in Chronic Kidney Disease — London, Ontario
- Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) — Birmingham, Alabama
- Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease — Cleveland, Ohio
- Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) — Birmingham, Alabama
Explore by condition: All Chronic Kidney Disease(CKD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.